NASDAQ:MREO Mereo BioPharma Group Q2 2026 Earnings Report $0.28 -0.01 (-2.73%) Closing price 04:00 PM EasternExtended Trading$0.28 +0.00 (+0.50%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Mereo BioPharma Group EPS ResultsActual EPS-$0.01Consensus EPS -$0.01Beat/MissMet ExpectationsOne Year Ago EPSN/AMereo BioPharma Group Revenue ResultsActual RevenueN/AExpected Revenue$3.50 millionBeat/MissN/AYoY Revenue GrowthN/AMereo BioPharma Group Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateTuesday, August 11, 2026Conference Call Time8:00AM ETUpcoming EarningsMereo BioPharma Group's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Quarterly report(10-Q) Mereo BioPharma Group Earnings HeadlinesMereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Consensus Rating of "Hold" by AnalystsAugust 23 at 2:44 AM | americanbankingnews.comJPMorgan Chase & Co. Reaffirms "Underweight" Rating for Mereo BioPharma Group (NASDAQ:MREO)August 21, 2026 | americanbankingnews.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.August 25 at 1:00 AM | Altimetry (Ad)Mereo BioPharma Group plc: Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung ...August 11, 2026 | finanznachrichten.deMereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate HighlightsAugust 11, 2026 | markets.businessinsider.comMereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)August 11, 2026 | markets.businessinsider.comSee More Mereo BioPharma Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mereo BioPharma Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mereo BioPharma Group and other key companies, straight to your email. Email Address About Mereo BioPharma GroupMereo BioPharma Group (NASDAQ:MREO) plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate. Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases. Additional clinical programs target oncology and immunology indications, leveraging both internally developed molecules and partnerships with third-party biotech and pharmaceutical companies. The company conducts multi‐center trials in Europe and North America, collaborating with academic institutions and contract research organizations to advance its clinical objectives. Established in 2013 and headquartered in London, Mereo BioPharma has built a team with expertise in clinical development, regulatory affairs and corporate strategy to support its focused portfolio. The company’s business strategy emphasizes strategic alliances, out-licensing opportunities and selective acquisitions to enhance shareholder value and ensure sustained progress across its pipeline. Mereo is listed on the NASDAQ under the ticker symbol MREO and maintains operations in the United Kingdom, United States and Europe.View Mereo BioPharma Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DICK's Sporting Goods Faces Pain Now for a Bigger PrizeStoneX: Too Far Too Fast?Pathward’s Credit Scare Tests Its Comeback StoryNVIDIA Earnings Could Move These 3 AI Stocks—Here’s What to WatchBeyond Big Tech: 3 Non-Tech Earnings Winners to WatchThe Bull Case for D-Wave After a Disappointing Earnings SeasonVisa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Upcoming Earnings Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026)Autodesk (8/27/2026)Marvell Technology (8/27/2026)Medtronic (9/1/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
